Careers  |  Sign In  |  Register

NSCLC Content Hub

VISION Trial Produces Positive Data in NSCLC With MET Exon 14 Mutations

Xiuning Le, MD, PhD, an assistant professor in the Department of Thoracic Head and Neck Medical Oncology, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, highlights positive results from the VISION clinical trial for non-small cell lung cancer (NSCLC). The VISION trial is for NSCLC patients with MET exon 14 skipping mutations. Of the 99 patients in the trial, patients had an objective response rate of 46%, with most patients exhibiting approximately 90% tumor shrinkage.

Click here to learn more.